We like to stay current on all things cannabis in the news, and breathless new headlines are buzzing about CBG, a cannabinoid that could be the new CBD. Research, as ever, is wildly preliminary, but encouraging and exciting nonetheless. Here’s what we know, and whether it means we should all be getting excited about CBG.
The cannabis plant has a lot of cannabinoids, and we’re still scratching the surface of these compounds. Cannabigerol is one of them. It’s considered a minor cannabinoid, because it’s found in extremely low levels in most strains — usually less than one percent. CBGA, or cannabigerolic acid, is actually a kind of parent compound to THCA, CBDA, and another compound, cannabichromenic acid, or CBCA. As plant enzymes break down CBGA, it becomes the cannabinoids we know and love — CBD and THC. That’s good and bad. The higher the percentage of CBD or THC, the less CBG. But breeders are already experimenting to create higher CBG strains, so stay tuned.
What we Know about CBG
Like the heavy hitters, CBG acts on specific physiological systems in the body by virtue of the CB1 and CB2 receptors in the endocannabinoid system. Right now, researchers think CBG could be even more directly effective than CBD, and it shares the same non-intoxicating quality. Research is still limited, but the animal and pre-clinical studies we do have are showing CBG may be effecting in treating:
- Anxiety disorders
- Inflammatory bowel conditions like Crohn’s disease or ulcerative colitis
- Movement disorders, such as Parkinson’s disease, Huntington’s disease, and multiple sclerosis
Because it’s non-intoxicating, CBG could also show promise as an analgesic, antidepressant, or as a treatment for skin conditions like psoriasis.
Early research is showing promise, and researchers are looking forward to seeing what CBG can do alone or in combination with other cannabinoids. So should we all be getting excited about CBG? Definitely!